Phase I study to assess the safety of long-term administration of DMSA (dimercaptosuccinic acid), a chelating agent which has been found to partially solubilize transthyretin in vitro, in patients with familial amyloidosis who are not eligible for liver transplantation.
Showing the most recent 10 out of 470 publications